Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Grimm

Showing results (51-60 of 207) with videos related to

Pageof 21
Sort By:
International Journal of Molecular Sciences|March 25, 2017
The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase InhibitorsOle Vincent Ancker, Markus Wehland, Johann Bauer, et al.
Basic & Clinical Pharmacology & Toxicology|August 18, 2015
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart FailureMathilde Borring Andersen, Ulf Simonsen, Markus Wehland, et al.
Biomed Research International|February 5, 2015
Simulated microgravity: critical review on the use of random positioning machines for mammalian cell cultureSimon L Wuest, Stéphane Richard, Sascha Kopp, et al.
Current Vascular Pharmacology|February 20, 2014
Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical ApplicationOle H Nielsen, Daniela Grimm, Markus Wehland, et al.
Basic & Clinical Pharmacology & Toxicology|May 3, 2018
A Focus on Macitentan in the Treatment of Pulmonary Arterial HypertensionMartin Bedan, Daniela Grimm, Markus Wehland, et al.
Current Pharmaceutical Design|July 19, 2016
Latest Results for Anti-Angiogenic Drugs in Cancer TreatmentSofie Frandsen, Sascha Kopp, Markus Wehland, et al.
Endocrinology|November 11, 2003
Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal studyJohann Schoenberger, Daniela Grimm, Peter Kossmehl, et al.
Current Vascular Pharmacology|October 26, 2011
The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular diseaseMarkus Wehland, Jirka Grosse, Ulf Simonsen, et al.
International Journal of Molecular Sciences|August 12, 2022
Microgravity-Related Changes in Bone Density and Treatment Options: A Systematic ReviewRonni Baran, Markus Wehland, Herbert Schulz, et al.
Physiological Reports|June 14, 2021
SARS-CoV-2 and hypertensionBriyanth Ravichandran, Daniela Grimm, Marcus Krüger, et al.
Pageof 21

Showing results (51-60 of 207) with videos related to

Sort By:
Pageof 21
International Journal of Molecular Sciences|March 25, 2017
The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase InhibitorsOle Vincent Ancker, Markus Wehland, Johann Bauer, et al.
Basic & Clinical Pharmacology & Toxicology|August 18, 2015
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart FailureMathilde Borring Andersen, Ulf Simonsen, Markus Wehland, et al.
Biomed Research International|February 5, 2015
Simulated microgravity: critical review on the use of random positioning machines for mammalian cell cultureSimon L Wuest, Stéphane Richard, Sascha Kopp, et al.
Current Vascular Pharmacology|February 20, 2014
Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical ApplicationOle H Nielsen, Daniela Grimm, Markus Wehland, et al.
Basic & Clinical Pharmacology & Toxicology|May 3, 2018
A Focus on Macitentan in the Treatment of Pulmonary Arterial HypertensionMartin Bedan, Daniela Grimm, Markus Wehland, et al.
Current Pharmaceutical Design|July 19, 2016
Latest Results for Anti-Angiogenic Drugs in Cancer TreatmentSofie Frandsen, Sascha Kopp, Markus Wehland, et al.
Endocrinology|November 11, 2003
Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal studyJohann Schoenberger, Daniela Grimm, Peter Kossmehl, et al.
Current Vascular Pharmacology|October 26, 2011
The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular diseaseMarkus Wehland, Jirka Grosse, Ulf Simonsen, et al.
International Journal of Molecular Sciences|August 12, 2022
Microgravity-Related Changes in Bone Density and Treatment Options: A Systematic ReviewRonni Baran, Markus Wehland, Herbert Schulz, et al.
Physiological Reports|June 14, 2021
SARS-CoV-2 and hypertensionBriyanth Ravichandran, Daniela Grimm, Marcus Krüger, et al.
Pageof 21